Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study.

CONCLUSION: Antibody responses induced by the 3-dose qHPV vaccination regimen in Chinese girls aged 9-19 years were non-inferior to those in Chinese young women aged 20-26 years. The vaccine was generally well tolerated in the study population. ClinicalTrials.gov Identifier: NCT03493542. PMID: 33239228 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33239228?dopt=Abstract

Source: Vaccine - November 22, 2020 Category: Allergy & Immunology Authors: Huang Z, He J, Su J, Ou Z, Liu G, Fu R, Shou Q, Zheng M, Group T, Luxembourg A, Liao X, Zhang J Tags: Vaccine Source Type: research